Skip to main content
OpenTrials
Completed

NCT Number: NCT06174779

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kangbuk samsung hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with following criteria :
  • BMI ≥ 30 kg/m2 or
  • 27 kg/m2 ≤ BMI < 30 kg/m2 with more than one risk factors or comorbidities(hypertension, dyslipidemia, sleep apnea, cardiocerebrovascular disease)
  • A person who have failed at least once to weight control using diet and exercise therapy before screening visit.

Exclusion criteria

  • A person whose weight change exceeds 5kg within 3 months prior to screening visit.
  • Diabetes mellitus (Type 1, type 2, etc.) or HbA1c ≥ 6.5 %.
  • Administration of hypoglycemic agents.
  • Administration of medicines inducing weight gain.
  • Prader-Willi Syndrome or MC4R deficiency.
  • Cushing's Syndrome.
  • Administration of medicines for weight management.
  • A person who has a history of surgery(including device-based therapy) related to obesity or who has a plan during the clinical trial period.
  • Administration of Steroids for the systemic use.
  • Clinically significant gastric emptying abnormalities.
  • History(including family history) of medullary thyroid carcinoma or multiple endocrine adenomatosis.
  • History of acute or chronic pancreatitis.
  • A person who has the following clinical laboratory test results :
  • TSH < 0.4 mIU/L or TSH > 6 mIU/L
  • Calcitonin > 100 ng/L
  • Amylase or Lipase > 3 x UNL
  • Severe liver disease (AST or AST > 3 x UNL or Total bilirubin > 1.5 x UNL).
  • Severe renal disease ( eGFR < 30mL/min/1.73m 2 ).
  • QTc > 450 ms.
  • Answered 'yes' to question 4 or 5 of the suicidal ideation domain in C-SSRS or history of suicide attempt.
  • PHQ-9 ≥ 15 or history of depression, anxiety, and other severe Mental illness.
  • History of alcohol addiction or drug abuse.
  • History of malignant tumors.
  • History of severe heart disease or severe neurovascular disease.
  • Hypersensitivity to investigational products or multi-drug allergy.
  • Positive to pregnancy test, nursing mother, intention on pregnancy.
  • Considered by investigator as not appropriate to participate in the clinical study with other reason.

Treatment and study plan

HM11260C

Drug

Test drug

Placebo

Drug

Placebo drug

Primary outcomes

  1. The percent change of body weight from baseline

    Time frame: baseline, 40 weeks

  2. The proportion of subjects achieving body weight loss ≥ 5% from baseline

    Time frame: baseline, 40 weeks

Secondary outcomes

  1. The percent change of body weight from baseline

    Time frame: baseline, 24 weeks, 64 weeks

  2. The proportion of subjects achieving body weight loss ≥ 5% from baseline

    Time frame: baseline, 24 weeks, 64 weeks

  3. The proportion of subjects achieving body weight loss ≥ 10% from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  4. Change of body weight from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  5. Change of BMI from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  6. Change of waist circumference from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  7. Change of glucose metabolism parameters from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  8. The percentage change of lipid profile parameters from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  9. Change of blood pressure from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  10. Change of IWQoL-Lite-CT(Physical function domain) from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

Sponsors and collaborators

Lead sponsor

Hanmi Pharmaceutical Company Limited

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Dec 18, 2023
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.